Home/Filings/4/0001628280-25-010224
4//SEC Filing

Waltermire Robert E. 4

Accession 0001628280-25-010224

CIK 0001157601other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 9:24 PM ET

Size

6.9 KB

Accession

0001628280-25-010224

Insider Transaction Report

Form 4
Period: 2025-02-28
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Transactions
  • Sale

    Common Stock

    2025-02-28$340.99/sh1,052$358,7173,903 total
  • Sale

    Common Stock

    2025-02-28$341.55/sh175$59,7713,728 total
Footnotes (2)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.495 to $341.415, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnote below.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.52 to $341.57, inclusive.

Issuer

MADRIGAL PHARMACEUTICALS, INC.

CIK 0001157601

Entity typeother

Related Parties

1
  • filerCIK 0001876996

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 9:24 PM ET
Size
6.9 KB